Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-lactalbumin Vaccine in High-Risk Triple-Negative Breast Cancer
NCT04674306Phase 1Completed
- Start
- Oct 2021
- Primary completion
- Dec 2025
- Modality
- Albumin, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of alpha-lactalbumin in triple-negative breast cancer (TNBC) (3 arms). Primary endpoint: Maximum Tolerated Dose at Day 84. Started Oct 2021; status: completed.
02
Drugs
alpha-lactalbumin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04674306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04674306.